PAOLI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.444
EU - Europa 1.447
AS - Asia 936
SA - Sud America 78
Continente sconosciuto - Info sul continente non disponibili 64
AF - Africa 30
OC - Oceania 7
Totale 5.006
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.400
RU - Federazione Russa 494
IT - Italia 474
SG - Singapore 263
CN - Cina 248
HK - Hong Kong 156
IE - Irlanda 91
SE - Svezia 80
VN - Vietnam 77
KR - Corea 69
BR - Brasile 59
FR - Francia 58
FI - Finlandia 52
DE - Germania 48
PL - Polonia 43
JO - Giordania 33
CA - Canada 29
CH - Svizzera 26
GB - Regno Unito 25
NL - Olanda 23
IN - India 22
BD - Bangladesh 19
ID - Indonesia 13
ES - Italia 12
TR - Turchia 8
AU - Australia 7
MX - Messico 7
AR - Argentina 6
JP - Giappone 6
CI - Costa d'Avorio 5
NG - Nigeria 5
UA - Ucraina 4
DZ - Algeria 3
EC - Ecuador 3
IQ - Iraq 3
JM - Giamaica 3
KE - Kenya 3
MY - Malesia 3
PK - Pakistan 3
RO - Romania 3
VE - Venezuela 3
ZA - Sudafrica 3
AT - Austria 2
BJ - Benin 2
CL - Cile 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ET - Etiopia 2
IR - Iran 2
MA - Marocco 2
MM - Myanmar 2
NO - Norvegia 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BS - Bahamas 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
PE - Perù 1
PY - Paraguay 1
SA - Arabia Saudita 1
SN - Senegal 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 4.944
Salva come PNG Salva come JPEG
Città #
Santa Clara 502
Ashburn 325
Fairfield 191
Singapore 191
Hong Kong 133
Woodbridge 94
Chandler 93
Dublin 91
San Jose 83
Seattle 81
Houston 74
Cambridge 72
Milan 71
Seoul 69
Florence 64
Wilmington 61
Beijing 49
Hefei 44
Warsaw 43
Altamura 37
Los Angeles 35
Rome 33
Council Bluffs 31
Lawrence 30
Dallas 28
Princeton 28
Bern 26
Helsinki 24
Ann Arbor 23
Ho Chi Minh City 23
Lauterbourg 23
Paris 22
Buffalo 21
The Dalles 21
Shanghai 17
Moscow 16
Munich 16
Clifton 15
Turku 15
Boston 14
London 14
New York 14
Atlanta 13
Jakarta 12
Medford 12
Boardman 11
Mumbai 11
Bremen 10
Da Nang 10
Hanoi 10
Naples 9
Toronto 9
Kent 8
Redondo Beach 8
Waltham 8
Amsterdam 7
Figino 7
Melbourne 7
São Paulo 7
Bergamo 6
Dearborn 6
Frosinone 6
Montreal 6
San Diego 6
Abidjan 5
Abuja 5
Ankara 5
Frankfurt am Main 5
Lappeenranta 5
Latina 5
Tokyo 5
Turin 5
Barcelona 4
Biên Hòa 4
Brescia 4
Cagliari 4
Chennai 4
Dong Ket 4
Düsseldorf 4
Falls Church 4
Monza 4
Napoli 4
Norwalk 4
Pomigliano d'Arco 4
Siena 4
Tianjin 4
Amman 3
Andover 3
Bari 3
Brooklyn 3
Bắc Ninh 3
Charleston 3
Chengdu 3
Faenza 3
Haiphong 3
Mexico City 3
Miano 3
Modena 3
Nairobi 3
Orem 3
Totale 3.184
Salva come PNG Salva come JPEG
Nome #
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 399
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 269
Sviluppo e gestione di studi clinici indipendenti di Fase I/II nelle Neoplasie Mieloproliferative Croniche 256
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 242
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 221
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 218
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 202
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 196
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 196
Kaposi Sarcoma in a patient treated with Ruxolitinib 194
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 192
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 191
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 190
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 187
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 185
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 184
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group 180
Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms 179
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 179
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 170
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 159
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 154
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs 152
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 149
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 143
Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency 19
Totale 5.006
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.345
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022149 0 11 15 4 3 7 5 20 11 6 22 45
2022/2023505 43 96 34 29 29 77 61 28 60 6 15 27
2023/2024233 12 20 24 21 17 24 5 68 6 13 12 11
2024/20251.472 49 115 79 237 374 244 38 108 44 57 66 61
2025/20261.564 172 187 122 93 177 57 208 73 93 115 62 205
2026/2027242 66 176 0 0 0 0 0 0 0 0 0 0
Totale 5.006